Advances in targeted therapy for unresectable melanoma: New drugs and combinations

Cancer Letters

Volumn 359, Issue 1, 2015, Pages 1-8

  Hao, Mengze ^a   Song, Fengju ^a   Du, Xiaoling ^a   Wang, Guowen ^a   Yang, Yun ^a   Chen, Kexin ^a   Yang, Jilong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

BRAF; C KIT; CTLA 4; MEK; PD 1 L1; PI3K Akt mTOR

Indexed keywords

BEVACIZUMAB; BINIMETINIB; BUPARLISIB; CARBOPLATIN; COBIMETINIB; DABRAFENIB; DACARBAZINE; EVEROLIMUS; GANETESPIB; IMATINIB; IPILIMUMAB; NILOTINIB; NIVOLUMAB; OBLIMERSEN; PACLITAXEL; PEMBROLIZUMAB; PLACEBO; SELUMETINIB; SORAFENIB; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; VEMURAFENIB; ANGIOGENESIS INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACNE; ADVERSE OUTCOME; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; HUMAN; HYPERTENSION; HYPOPHYSITIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; SHORT SURVEY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MELANOMA; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME; TRENDS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84922265201     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.050     Document Type: Review

References (91)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63:11-30.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin 2012, 62:10-29.
3. Ott P.A., Hamilton A., Min C., Safarzadeh-Amiri S., Goldberg L., Yoon J., et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 2010, 5:e15588.
4. Sorof T.A., Hallmeyer S., Hamid O., et al. Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9075). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9075?sid=3836ae88-89c5-41cd-8d7f-f855bfcf7fab.
5. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
6. Kim K.B., Kefford R., Pavlick A.C., Infante J.R., Ribas A., Sosman J.A., et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol 2013, 31:482-489.
7. Robert C., Dummer R., Gutzmer R., Lorigan P., Kim K.B., Nyakas M., et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013, 14:733-740.
8. Ascierto P.A., Schadendorf D., Berking C., Agarwala S.S., van Herpen C.M., Queirolo P., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
9. Guo J., Si L., Kong Y., Flaherty K.T., Xu X., Zhu Y., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol 2011, 29:2904-2909.
10. Cho J.H., Kim K.M., Kwon M., Kim J.H., Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest. New Drugs 2012, 30:2008-2014.
11. Schuster C., Eikesdal H.P., Puntervoll H., Geisler J., Geisler S., Heinrich D., et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS ONE 2012, 7:e38364.
12. Del Vecchio M., Mortarini R., Canova S., Di Guardo L., Pimpinelli N., Sertoli M.R., et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin. Cancer Res 2010, 16:5862-5872.
13. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med 2010, 363:711-723.
14. Robert C., Thomas L., Bondarenko I., O'Day S., C.Garbe D.J.M., Lebbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med 2011, 364:2517-2526.
15. Stones C.J., Kim J.E., Joseph W.R., Leung E., Marshall E.S., Finlay G.J., et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Frontiers Genet 2013, 4.
16. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. NEJM 2012, 367:107-114.
17. Amaravadi R.K., Schuchter L.M., McDermott D.F., Kramer A., Giles L., Gramlich K., et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res 2009, 15:7711-7718.
18. Maki R.G., D'Adamo D.R., Keohan M.L., Saulle M., Schuetze S.M., Undevia S.D., et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol 2009, 27:3133-3140.
19. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med 2012, 366:707-714.
20. Beck D., Niessner H., Smalley K.S., Flaherty K., Paraiso K.H., Busch C., et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci. Signal 2013, 6:ra7.
21. Trunzer K., Pavlick A.C., Schuchter L., Gonzalez R., McArthur G.A., Hutson T.E., et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol 2013, 31:1767-1774.
22. Menzies A.M., Chan M., Haydu L., et al. Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD). J. Clin. Oncol. (Meeting Abstracts) 2013, 31(15_suppl 9062). Available from:, 2013. http://meeting.ascopubs.Org/cgi/content/abstract/31/15_suppl/9062?sid=e2f2bfb8-71dd-4214-8e58-2e085ba12770.
23. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
24. Hess J., Ruf P., Lindhofer H. Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol 2012, 8:73-85.
25. Varker K.A., Biber J.E., Kefauver C., Jensen R., Lehman A., Young D., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol 2007, 14:2367-2376.
26. Avril M.F., Aamdal S., Grob J.J., Hauschild A., Mohr P., Bonerandi J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J. Clin. Oncol 2004, 22:1118-1125.
27. Spagnolo F., Queirolo P., Picasso V., et al. BeyPro1: a phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine. J. Clin. Oncol 2014, 32(5s). 2014 (suppl; abstr TPS9109). 2014 ASCO Annual Meeting.
28. Queirolo P., Ascierto P.A., Flaherty K., et al. Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9105). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS9105?sid=7d479ce3-8d79-402c-955b-3cfed1c882c9.
29. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
30. Ribas A., Ascierto P.A., Minor D.R., et al. Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9034). Available from:, 2014, Melanoma/Skin Cancers. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9034?sid=72778a5e-e645-47a8-ac82-4a4fce14fd43.
31. Ribas A., Hodi F.S., Callahan M., Konto C., Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med 2013, 368:1365-1366.
32. Linette G.P., Puzanov I., Callahan M.K., et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9034). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2511?sid=117d037f-5de6-4fcf-85d8-c4ebe9c8cdb7.
33. Falchook G.S., Lewis K.D., Infante J.R., Gordon M.S., Vogelzang N.J., DeMarini D.J., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:782-789.
34. Gogas H., Long G.V., Stroyakovsky D.L., et al. COMBI-d: a randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/Kmutation-positive cutaneous melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9011). Available from:. http://meeting.ascopubs.Org/cgi/content/abstract/32/15_suppl/9011?sid=77fb0735-c095-4001-a6c9-5beb723ac32d.
35. Dummer R., Gogas H., Schadendorf D., et al. Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9061). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9061?sid=26c791af-551d-4bb3-9dff-5e51ef294340.
36. Yeh T.C., Marsh V., Bernat B.A., Ballard J., Colwell H., Evans R.J., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res 2007, 13:1576-1583.
37. Banerji U., Camidge D.R., Verheul H.M., Agarwal R., Sarker D., Kaye S.B., et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res 2010, 16:1613-1623.
38. Kirkwood J.M., Bastholt L., Robert C., Sosman J., Larkin J., Hersey P., et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res 2012, 18:555-567.
39. Goel V.K., Lazar A.J., Warneke C.L., Redston M.S., Haluska F.G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol 2006, 126:154-160.
40. Jakob J.A., Bassett R.L., Ng C.S., Curry J.L., Joseph R.W., Alvarado G.C., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
41. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
42. Ascierto P.A., Flaherty K., Arenberger P., et al. NEMO: a phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9102). Available from:. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS9102?sid=e78cc5fa-9a4f-4b29-b13c-ee54ab88d081.
43. Grilley-Olson J.E., Weiss G.J., et al. A dose-escalation phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: dose escalation with an intermittent 28 days on/14 days off schedule. J. Clin. Oncol. (Meeting Abstracts) 2012, 30(15_suppl 3046). Available from:. http://meeting.ascopubs.Org/cgi/content/abstract/30/15_suppl/3046?sid=f988be5b-6de4-4888-b340-708f51f6d36a.
44. Moseley J., Mita M.M., Mita A.C., et al. A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: final results. J. Clin. Oncol. (Meeting Abstracts) 2012, 29(15_suppl 3080). Available from:, 2011. http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/3080?sid=1082a9b9-aa03-451d-8895-e16d81714cbb.
45. Lolkema M.P.J.K., Sosman J.A., Kittaneh M., et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9009). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9009?sid=a70a4357-b3df-462a-9a65-ee65a26bcfc8.
46. Shahheydari H., Carlino M.S., Fung C., et al. Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9004). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9004?sid=976aae26-de7e-4828-a744-b318eeb72501.
47. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med 2012, 367:1694-1703.
48. Weber J.S., Flaherty K., Daud A., et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9010). Available from:. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9010?sid=f34b15b1-6098-4df4-8792-6bcbabcacc99.
49. Lawrence D.P., Gordon M.S., Lutzky J., et al. Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9108). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS9108?sid=010fd00f-6141-4157-9acc-a93473f01188.
50. Helwick C. Metastatic Melanoma: Encouraging Data Keep Coming http://www.ascopost.com/issues/december-1,-2013/metastatic-melanoma-encouraging-data-keep-coming.aspx.
51. Faja L.R., Hu-Lieskovan S., Mok S., et al. Combinatorial effect of dabrafenib, trametinib, and adoptive cell transfer (ACT) in an immune-competent murine model of BRAFV600E mutant melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 2512). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2512?sid=0a90745c-e66b-4f2d-90a9-0997a7d2adfb.
52. Callahan J., McArthur G.A., et al. Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9006). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9006?sid=1af3f25e-ef6b-41e8-94f7-15cd507b7043.
53. Hodi F.S., Corless C.L., Giobbie-Hurder A., Fletcher J.A., Zhu M., Marino-Enriquez A., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol 2013, 31:3182-3190.
54. Wang X., Si L., Kong Y., et al. A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma. J. Clin. Oncol. (Meeting Abstracts) 2013, 31(15_suppl 20027). Available from:, 2013. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e20027?sid=04053ccc-c7ef-4f03-8831-562ca86b3443.
55. Tran A., Tawbi H.A. A potential role for nilotinib in KIT-mutated melanoma. Expert Opin. Investig. Drugs 2012, 21:861-869.
56. Chevret S., Lebbe C., Jouary T., Dalac S. Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification. J. Clin. Oncol. (Meeting Abstracts) 2014, 2:755-759. Available from:, 2014, Vol. 32, No. 15_suppl 9032. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032?sid=5c58c99f-0985-419d-a2a4-24cb9f4941d3.
57. Otrock Z.K., Makarem J.A., Shamseddine A.I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol. Dis 2007, 38:258-268.
58. Gonzalez-Cao M., Viteri S., Diaz-Lagares A., Gonzalez A., Redondo P., Nieto Y., et al. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 2008, 74:12-16.
59. Perez D.G., Suman V.J., Fitch T.R., Amatruda T., Morton R.F., Jilani S.Z., et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009, 115:119-127.
60. Slingluff C.L., Petroni G.R., Molhoek K.R., Brautigan D.L., Chianese-Bullock K.A., Shada A.L., et al. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin. Cancer Res 2013, 19:3611-3620.
61. Wang X.Y., Cheng Y., Du J.P., Chen D.G., Yang X.S., Yang Z.M., et al. [Synergistic effect of targeted inhibition of MEK/ERK and PI3K/AKT survival signaling pathways on induction of apoptosis in melanoma]. Sichuan Da Xue Xue Bao Yi Xue Ban 2014, 45:355-361.
62. Hainsworth J.D., Infante J.R., Spigel D.R., Peyton J.D., Thompson D.S., Lane C.M., et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010, 116:4122-4129.
63. Dronca R.S., Allred J.B., Perez D.G., Nevala W.K., Lieser E.A., Thompson M., et al. Phase II Study of Temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group Study, N0675. Am. J. Clin. Oncol 2014, 37:369-376.
64. Allred J., Dronca R.S., Perez D.G., Maples W.J., et al. N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM). J. Clin. Oncol. (Meeting Abstracts) 2010, 28(15_suppl 8572). Available from:, 2010. http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8572?sid=35c1ff0f-0a37-4951-904d-433780c96043.
65. Meier F.E., Niessner H., et al. The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. J. Clin. Oncol. (Meeting Abstracts) 2013, 31(15_suppl 20050). Available from:, 2013. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e20050?sid=5f8cd14a-ceda-4520-84d8-50e3c673f39b.
66. Rodon J., Brana I., Siu L.L., De Jonge M.J., Homji N., Mills D., et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest. New Drugs 2014, 32:670-681.
67. Kurzrock R., Bedard P., Tabernero J., et al. A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) 2012, 30(15_suppl 3003). Available from:, 2012. http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/3003?sid=a8a13f33-f324-4020-854a-99a4e98978f1.
68. Ortiz-Urda S., Algazi A.P., Posch C., et al. BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: two cases. J. Clin. Oncol. (Meeting Abstracts) 2013, 31(15_suppl 20010). Available from:, 2013. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e20010?sid=15a31b29-ec58-467f-baac-0bc9bd2fb7c5.
69. Kantor A., Daud A., et al. A phase I/II trial of BKM120 combined with vemurafenib (PLX4032) in BRAFV600E/k mutant advanced melanoma. J. Clin. Oncol. (Meeting Abstracts) 2012, 30(15_suppl 8602). Available from:. http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/TPS8602?sid=66d2096a-12de-4bcd-931e-c210678b1089.
70. Wu X., Marmarelis M.E., Hodi F.S. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS ONE 2013, 8:e56134.
71. Acquaviva J., Smith D.L., Jimenez J.P., Zhang C., Sequeira M., He S., et al. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with Ganetespib. Mol. Cancer Ther 2014, 13:353-363.
72. Di Cresce C., Koropatnick J. Antisense treatment in human prostate cancer and melanoma. Curr. Cancer Drug Targets 2010, 10:555-565.
73. Bedikian A.Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol 2006, 24:4738-4745.
74. Ott P.A., Chang J., Madden K., Kannan R., Muren C., Escano C., et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother. Pharmacol 2013, 71:183-191.
75. Aixinjueluo W., Furukawa K., Zhang Q., Hamamura K., Tokuda N., Yoshida S., et al. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J. Biol. Chem 2005, 280:29828-29836.
76. Navid F., Santana V.M., Barfield R.C. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets 2010, 10:200-209.
77. Chelius D., Ruf P., Gruber P., Ploscher M., Liedtke R., Gansberger E., et al. Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs 2010, 2:309-319.
78. Ruf P., Schafer B., Eissler N., Mocikat R., Hess J., Ploscher M., et al. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. J. Transl. Med 2012, 10:219.
79. Kubica A.W., Brewer J.D. Melanoma in immunosuppressed patients. Mayo Clin. Proc 2012, 87:991-1003.
80. Shahabi V., Whitney G., Hamid O., Schmidt H., Chasalow S.D., Alaparthy S., et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol. Immunother 2012, 61:733-737.
81. Grob J.J., Eggermont A.M., Chiarion-Sileni V., et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(18_suppl 9008). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/18_suppl/LBA9008?sid=cf2289b1-9471-49ab-999a-833d814ad57c.
82. De Sousa S.M., Long G.V., Tonks K.T. Ipilimumab-induced hypophysitis: early Australian experience. Med. J. Aust 2014, 201:198-199.
83. Kirkwood J.M., Lorigan P., Hersey P., Hauschild A., Robert C., McDermott D., et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res 2010, 16:1042-1048.
84. Milhem M.M., Puzanov I., et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9029). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9029?sid=9ac96fb4-720a-45e4-a0f1-67181e9b2f6e.
85. Collichio F.A., Kaufman H.L., Andtbacka R.H.I., et al. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9008). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9008a?sid=a6afe035-0e6e-4355-b3f1-c0318d8c772b.
86. Sznol M., Hodi F.S., et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 9002). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9002?sid=15cd362d-902c-45d6-a059-f801643187de.
87. Gibney G.T., Weber J.S., Kudchadkar R.R., et al. Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI). J. Clin. Oncol. (Meeting Abstracts) 2014, 32(15_suppl 3009). Available from:, 2014. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3009?sid=d6fe8c0e-3901-4b58-805f-c2257c225f20.
88. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
89. Kefford R., Ribas A., Stephen Hodi F., et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J. Clin. Oncol. (Meeting Abstracts) 2014, 32(18_suppl 9000). Available from:. http://meeting.ascopubs.org/cgi/content/abstract/32/18_suppl/LBA9000?sid=8b6bc2f1-b7bf-465c-8f57-a043933e16a4.
90. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med 2013, 369:122-133.
91. Callahan M.K., Sznol M., Kluger H.M., et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J. Clin. Oncol. (Meeting Abstracts) 2014, 32(18_suppl 9003). Available from:. http://meeting.ascopubs.Org/cgi/content/abstract/32/18_suppl/LBA9003?sid=64f64f30-40d7-4771-be01-88c2d1321c3a.